FDA oncology panel votes against AstraZeneca's camizestrant trial, citing lack of meaningful benefit

The FDA's oncology advisory committee convened for the first time in about nine months and evaluated AstraZeneca's late-stage trial of its oral selective estrogen receptor degrader, camizestrant.

By a 6-3 vote, the panel concluded the study did not demonstrate a clinically meaningful benefit for patients, effectively rejecting the trial’s primary claim.

AstraZeneca had promoted the drug as a potential new paradigm for treating breast cancer, but the advisory decision represents a significant regulatory hurdle for the company's development program.

The outcome may delay further advancement of camizestrant and could impact investor expectations for AstraZeneca's oncology pipeline.